149 related articles for article (PubMed ID: 23589356)
1. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion.
Brogden NK; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Pharm Sci; 2013 Jun; 102(6):1948-1956. PubMed ID: 23589356
[TBL] [Abstract][Full Text] [Related]
2. Optimization of impedance spectroscopy techniques for measuring cutaneous micropore formation after microneedle treatment in an elderly population.
Kelchen MN; Holdren GO; Farley MJ; Zimmerman MB; Fairley JA; Brogden NK
Pharm Res; 2014 Dec; 31(12):3478-86. PubMed ID: 24947437
[TBL] [Abstract][Full Text] [Related]
3. Micropore closure kinetics are delayed following microneedle insertion in elderly subjects.
Kelchen MN; Siefers KJ; Converse CC; Farley MJ; Holdren GO; Brogden NK
J Control Release; 2016 Mar; 225():294-300. PubMed ID: 26829102
[TBL] [Abstract][Full Text] [Related]
4. Micropore closure time is longer following microneedle application to skin of color.
Ogunjimi AT; Carr J; Lawson C; Ferguson N; Brogden NK
Sci Rep; 2020 Nov; 10(1):18963. PubMed ID: 33144596
[TBL] [Abstract][Full Text] [Related]
5. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.
Brogden NK; Banks SL; Crofford LJ; Stinchcomb AL
Pharm Res; 2013 Aug; 30(8):1947-55. PubMed ID: 23761054
[TBL] [Abstract][Full Text] [Related]
6. Diclofenac delays micropore closure following microneedle treatment in human subjects.
Brogden NK; Milewski M; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Control Release; 2012 Oct; 163(2):220-9. PubMed ID: 22929967
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.
Ghosh P; Brogden NK; Stinchcomb AL
J Pharm Sci; 2014 Feb; 103(2):652-60. PubMed ID: 24395718
[TBL] [Abstract][Full Text] [Related]
8. Micropore Closure Rates following Microneedle Application at Various Anatomical Sites in Healthy Human Subjects.
Ogunjimi AT; Lawson C; Carr J; Patel KK; Ferguson N; Brogden NK
Skin Pharmacol Physiol; 2021; 34(4):214-228. PubMed ID: 33910205
[TBL] [Abstract][Full Text] [Related]
9. Impact of Formulation and Microneedle Length on Transdermal Metronidazole Permeation through Microneedle-Treated Skin.
Patel KK; Brogden NK
Pharm Res; 2024 Feb; 41(2):355-363. PubMed ID: 38133717
[TBL] [Abstract][Full Text] [Related]
10. A new paradigm for numerical simulation of microneedle-based drug delivery aided by histology of microneedle-pierced skin.
Han T; Das DB
J Pharm Sci; 2015 Jun; 104(6):1993-2007. PubMed ID: 25821048
[TBL] [Abstract][Full Text] [Related]
11. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive measurement of transdermal drug delivery by impedance spectroscopy.
Arpaia P; Cesaro U; Moccaldi N
Sci Rep; 2017 Mar; 7():44647. PubMed ID: 28338008
[TBL] [Abstract][Full Text] [Related]
13. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.
Banks SL; Pinninti RR; Gill HS; Paudel KS; Crooks PA; Brogden NK; Prausnitz MR; Stinchcomb AL
J Pharm Sci; 2010 Jul; 99(7):3072-80. PubMed ID: 20166200
[TBL] [Abstract][Full Text] [Related]
14. The Use of a Pressure-Indicating Sensor Film to Provide Feedback upon Hydrogel-Forming Microneedle Array Self-Application In Vivo.
Vicente-Pérez EM; Quinn HL; McAlister E; O'Neill S; Hanna LA; Barry JG; Donnelly RF
Pharm Res; 2016 Dec; 33(12):3072-3080. PubMed ID: 27633885
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of microneedles-assisted in situ depot forming poloxamer gels for sustained transdermal drug delivery.
Khan S; Minhas MU; Tekko IA; Donnelly RF; Thakur RRS
Drug Deliv Transl Res; 2019 Aug; 9(4):764-782. PubMed ID: 30675693
[TBL] [Abstract][Full Text] [Related]
16. Microneedle-Assisted Skin Permeation by Nontoxic Bioengineerable Gas Vesicle Nanoparticles.
Andar AU; Karan R; Pecher WT; DasSarma P; Hedrich WD; Stinchcomb AL; DasSarma S
Mol Pharm; 2017 Mar; 14(3):953-958. PubMed ID: 28068767
[TBL] [Abstract][Full Text] [Related]
17. Spatially controlled coating of continuous liquid interface production microneedles for transdermal protein delivery.
Caudill CL; Perry JL; Tian S; Luft JC; DeSimone JM
J Control Release; 2018 Aug; 284():122-132. PubMed ID: 29894710
[TBL] [Abstract][Full Text] [Related]
18. Formulation of hydrophobic peptides for skin delivery via coated microneedles.
Zhao X; Coulman SA; Hanna SJ; Wong FS; Dayan CM; Birchall JC
J Control Release; 2017 Nov; 265():2-13. PubMed ID: 28286315
[TBL] [Abstract][Full Text] [Related]
19. Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery.
Ghosh P; Brogden NK; Stinchcomb AL
Mol Pharm; 2013 Jun; 10(6):2331-9. PubMed ID: 23590208
[TBL] [Abstract][Full Text] [Related]
20. Effect of force of microneedle insertion on the permeability of insulin in skin.
Cheung K; Han T; Das DB
J Diabetes Sci Technol; 2014 May; 8(3):444-52. PubMed ID: 24876604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
